



#4

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Flodgaard et al.

Application No.: 09/559,764

Group Art Unit: TBA

Filed: April 27, 2000

Examiner: TBA

For: Inhibition Of Bradykinin Release

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. US 5,780,265
2. US 5,786,328
3. WO 93/05396
4. Petersen LC et al., MEDLINE, Dialog accession no. 07797095
5. Heinzelmann et al., Chemical Abstract no. 138095


6. Heinzelmann et al., Infection and Immunity, Vol. 66, No. 12, pp. 5842-5847 (Dec. 1998)
7. Petersen et al., Eur. J. Biochem., Vol. 214, pp. 271-279 (1993)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of the application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b). Therefore, no fee is due.

Respectfully submitted,

Date: August 14, 2000

  
Valeta A. Gregg, Reg. No. 35,127  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123